secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0000950170-25-086830
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed shareholders approve 2025 Equity Incentive Plan authorizing 4.5M new shares
--------------------------------------------------------------------------------

- Plan replaces prior stock option and restricted share unit plans; 4,500,000 common shares reserved.
- All six director nominees (Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone) elected with >99% votes for each.
- KPMG LLP ratified as independent auditor for the next year (42,583,160 for, 267,331 withheld).
- Plan approved by shareholders: 28,452,155 for, 581,911 against, 110,688 abstain, 13,705,737 broker non-votes.
- Annual meeting held June 12, 2025; 56.7% of outstanding shares voted, quorum present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025086830/0000950170-25-086830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025086830/mnmd-20250616.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-086830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer